However, the group could hit a ceiling here, according to Bill Baruch, president of Blue Line Futures.
"This sector has been on fire and to play devil's advocate I want to take a look at where the resistance can come in," Baruch told CNBC's "Trading Nation" on Thursday. "If you look back at the 2015 high, there's a trend line that goes up to that January high in XLV and that comes in just above the market around $95 or $96 so there is some headwind there."
The XLV ETF is still a 2.6 percent rally from $95, a level that would mark a record. It last hit an all-time high on Thursday.
Pfizer looks to be the sector's biggest winner, said Baruch.
"It's already broken out above [its own trend line] and now comes in as support at $40 so I like being long Pfizer. It's bullish right now and I think it could trade up through $45," he said.
Pfizer last set a record on Aug. 20, but has since pulled back around 3 percent. It would need to add nearly 9 percent to its current price to get to $45.
Gina Sanchez, CEO of Chantico Global, sees the health-care sector heading even higher as a shift in the market gives it a tail wind.
There's a "rotation toward more defensive stocks and health care is a very defensive sector when the market starts to turn," she said Thursday on "Trading Nation."
Defensive stocks, such as health care, tend to outperform when investors anticipate a slowdown in economic activity. These stocks are often used as a safe haven for investors during a downturn.
"We're not saying that the market is necessarily turning yet but we are seeing some signs and some canaries in the coal mine that tell us that the market is moving away from these high-flying momentum names into more robust and defensive names," Sanchez added.
The XLV ETF has added 12 percent so far this year, above the S&P 500's 8 percent advance.